Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Check-Cap Ltd Ord (CHEK)

Check-Cap Ltd Ord (CHEK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,113
  • Shares Outstanding, K 1,605
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,590 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.43
  • Number of Estimates 2
  • High Estimate -0.42
  • Low Estimate -0.43
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +14.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.90 +2.11%
on 08/16/19
2.29 -15.28%
on 07/18/19
-0.30 (-13.39%)
since 07/16/19
3-Month
1.90 +2.11%
on 08/16/19
2.80 -30.71%
on 05/17/19
-0.53 (-21.46%)
since 05/16/19
52-Week
1.62 +19.75%
on 12/21/18
4.50 -56.89%
on 09/04/18
-1.43 (-42.43%)
since 08/16/18

Most Recent Stories

More News
Check-Cap Reports Second Quarter 2019 Financial Results and Corporate Highlights

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free...

CHEK : 1.94 (+1.57%)
CHEKW : 0.04 (unch)
CHEKZ : 0.20 (-31.03%)
Check-Cap Announces Positive Final Results from Its Post-CE Approval Study of the C-Scan® System

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free...

CHEK : 1.94 (+1.57%)
CHEKW : 0.04 (unch)
CHEKZ : 0.20 (-31.03%)
Check-Cap Appoints Joshua (Shuki) Belkar as Vice President of Operations

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free...

CHEK : 1.94 (+1.57%)
CHEKW : 0.04 (unch)
CHEKZ : 0.20 (-31.03%)
Check-Cap to Present Data at Digestive Disease Week® Demonstrating Substantial Improvement in Precancerous Polyp Detection

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free...

CHEK : 1.94 (+1.57%)
CHEKW : 0.04 (unch)
CHEKZ : 0.20 (-31.03%)
Check-Cap Reports First Quarter 2019 Financial Results

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free...

CHEK : 1.94 (+1.57%)
CHEKW : 0.04 (unch)
CHEKZ : 0.20 (-31.03%)
Check-Cap Announces Second Trial Site Joins Ongoing U.S. Pilot Study of C-Scan®

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free...

CHEK : 1.94 (+1.57%)
CHEKW : 0.04 (unch)
CHEKZ : 0.20 (-31.03%)
Analysis: Positioning to Benefit within CRISPR Therapeutics AG, SPIRIT MTA REIT, Gaia, Perceptron, Check-Cap, and Key Tronic -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CRISPR Therapeutics AG (NASDAQ:CRSP),...

SMTA : 8.53 (-0.35%)
CRSP : 47.55 (+3.15%)
GAIA : 7.22 (-1.23%)
CHEK : 1.94 (+1.57%)
PRCP : 4.25 (-9.77%)
KTCC : 5.27 (+1.61%)
Check-Cap Initiates U.S. Pilot Study of C-Scan® for Colorectal Cancer Screening

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free...

CHEK : 1.94 (+1.57%)
CHEKW : 0.04 (unch)
CHEKZ : 0.20 (-31.03%)
Check-Cap Reports Fourth Quarter and Full-Year 2018 Financial Results

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free...

CHEK : 1.94 (+1.57%)
CHEKW : 0.04 (unch)
CHEKZ : 0.20 (-31.03%)
Check-Cap Announces Appointment of Mira Rosenzweig as Chief Financial Officer

Check-Cap Ltd. (the "Company" or "Check-Cap") (Nasdaq: CHEK) (Nasdaq: CHEKW), (Nasdaq: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free...

ELRN : 0.0011 (unch)
CHEK : 1.94 (+1.57%)
CAMT : 8.62 (+3.36%)
CHEKW : 0.04 (unch)
ENTX : 2.57 (-1.15%)
CHEKZ : 0.20 (-31.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CHEK with:

Business Summary

Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel.

See More

Key Turning Points

2nd Resistance Point 1.97
1st Resistance Point 1.95
Last Price 1.94
1st Support Level 1.91
2nd Support Level 1.89

See More

52-Week High 4.50
Fibonacci 61.8% 3.40
Fibonacci 50% 3.06
Fibonacci 38.2% 2.72
Last Price 1.94
52-Week Low 1.62

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar